Introduction of new techniques for disease diagnosis is a key factor driving
the global in-vitro diagnostics market, states Fortune Business Insights in a
report, titled “In-vitro Diagnostics Market Size, Share & Industry
Analysis, By Product Type (Instruments, Reagents & Consumables), By
Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point
of Care, Hematology and Others), By Application (Infectious Diseases,
Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical
Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast,
2019-2026.”
“Increasing Prevalence of Chronic and
Infectious Disease Will Enable Growth “
The launch of diagnostic and rapid testing
tools by leading market players will propel growth of the global in-vitrodiagnostics market. For instance, Thermo Fisher Scientific launched Phadia 200
for diagnosis of allergy & autoimmune conditions. The launch of Phadia 200
is anticipated to increase the revenue of the company. According to the report,
the reagents and consumables segment will account for a major portion in the
global in-vitro diagnostics market during the forecast period owing to the adoption
of self- test and point-of-care devices. Furthermore, the instrument segment is
likely to grow at a moderately slower pace during the forecast period. Rising
technological advancement is predicted to aid growth of the segment. Moreover,
the increasing cases of cancer and infectious disease around the world will
further accelerate global in-vitro diagnostics market growth.
“Launch of Altostar Molecular
Diagnostics Workflow Will Boost Growth”
Altona Diagnostics GmbH, molecular
diagnostic testing solutions company launched a CE-IVD marked AltoStar
Molecular Diagnostics Workflow. AltoStar Molecular Diagnostics a flexible and
efficient automatic system that automates the entire workflow from sample
preparation up to analysis. Fortune Business Insights states the launch of CE-IVD
marked AltoStar Molecular Diagnostics Workflow is expected to boost the in-vitro
diagnostics market revenue. Furthermore, the oncology segment is likely to grow
at a considerable rate during the forecast period. Rising adoption and
availability of advanced home care kits such as fecal occult blood test (FOBT)
for diagnosis of colon cancer in homecare settings is one of the major factor likely
to fuel demand for the oncology segment, which, will, in turn, uplift the
global in-vitro diagnostics market shares
Source:
No comments:
Post a Comment